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OBJECTIVES: A telecommunications company, a founding
member of the Leapfrog Group, undertook this study to evalu-
ate its costs for retirees with Type-2 diabetes and the quality of
care received. METHODS: Health care costs were evaluated for
those with 6 months continuous enrollment prior to, and 12
months after, an initial Type 2 diabetes medical service noted in
a claims database. Vascular complications (cardio-, cerebro-,
micro- and peripheral) were grouped into a cohort hierarchy for
analysis. Cost differences were estimated among groups adjust-
ing for age, gender and severity of concurrent conditions.
RESULTS: The mean age of the population (N = 9959) was 74.4
years; 50% were female. Adjusted annual costs for those without
hospitalizations ranged from $4877 with no complications to
$12,271 with four complications. For those with hospitaliza-
tions, adjusted annual costs ranged from $18,839 with one com-
plication to $41,011 with 4 complications. Each group was
signiﬁcantly different (p < 0.001) from the no complication
group. Average annual costs per beneﬁciary with/without 
hospitalizations were cardiovascular (excluding hyperten-
sion), $11,128/$22,952; hypertension, $7656/$17,927; stroke,
$15,349/$25,333. No antidiabetic drug was present in 4360
(44%) beneﬁciaries in the 12-month period after the initial dia-
betes medical service. Of the 5599 prescribed an antidiabetic
drug, 2072 (37%) received a sulfonylurea only; 913 (16%)
received a sulfonylurea and metformin; 698 (12%) received met-
formin only; 566 (10%) received insulin only; and, 573 (10%)
received a thiazolidinedione alone or in combination. CON-
CLUSIONS: Type-2 diabetes produces signiﬁcant health care
expenditures by an employer, its retirees and Medicare. Despite
a generous prescription beneﬁt, drug treatment patterns suggest
misuse of agents with known adverse effects and underuse of
agents with evidence-based therapeutic beneﬁts. These results
will support a targeted, evidenced-based, employer-sponsored
intervention to improve quality-of-care and patient safety by
focusing on drug treatment appropriate for the individual’s 
circumstances.
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OBJECTIVE: To quantify the effect of diabetes-related hypo-
glycemia on direct health care costs and utilization. METHODS:
The sample consisted of 9162 privately insured employees that
had at least 12 months of continuous enrollment between
January 1, 1999 and December 31, 2001, and two or more pre-
scriptions for diabetes-related medications within the same ther-
apeutic class (insulin, sulfonylurea, or other oral diabetes-related
medication) from Medstat’s Health Productivity and Manage-
ment database. Patients were grouped into two cohorts: hypo-
glycemia or non-hypoglycemia depending on whether they
incurred a diagnosis of hypoglycemia (ICD-9-CM 250.8, 251.1,
251.2). The sample was further sub-set to those with claims for
insulin (N = 2664)—64% of the original sample. Data were gath-
ered starting from the ﬁrst evidence of a diabetes-related med-
ication. RESULTS: The incidence of hypoglycemia did not vary
signiﬁcantly by age, insurance type, or region of the country.
However, the hypoglycemia group had evidence of signiﬁcantly
increased comorbidity including renal disease (14% vs. 6%, 
p < 0.01), ophthalmic ﬁndings (42% vs. 30%, p < 0.01), and
neuropathy (30% vs. 15%, p < 0.01), as well as a higher 
mean Charlson Comorbidity Index (1.20 vs. 0.75, p < 0.01).
Hypoglycemia patients incurred on average twice as many hos-
pitalizations (1.0 vs. 0.5, p < 0.01) and emergency room visits
(0.8 vs. 0.4, p < 0.01) annually compared to insulin-users
without hypoglycemia. Forty percent (40%) of the excess hos-
pitalizations and 53% of the excess emergency room visits were
associated with a hypoglycemia diagnosis. Hypoglycemia
patients on insulin incurred twice the amount of overall health
care expenditures ($28,049 vs. $14,019, p < 0.01) and three
times the amount of diabetes-related health care expenditures
($14,590 vs. $5236, p < 0.01) compared to non-hypoglycemia
insulin users. CONCLUSION: Hypoglycemia contributed sig-
niﬁcantly to medical care utilization and health care expenditures
among patients using insulin. Analysis of the indirect costs
among this population as well as investigation into hypoglycemia
among diabetes patients on oral agents warrants further investi-
gation.
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OBJECTIVES: Diabetes disproportionately affects the poor and
medically underserved minorities, populations typically served
by State Medicaid programs. This study sought to assess the pat-
terns of diabetes-related health care costs incurred by the Texas
Medicaid program for Hispanics, African-Americans, and Cau-
casians with type-2 diabetes. METHODS: Treatment-naïve adult
patients in 2000 were identiﬁed. Total costs were assessed in the
12-months following the initiation of therapy, deﬁned as the ﬁrst
ﬁlling of a prescription following 6 months of no such prescrip-
tion. Patient demographic and disease severity measures as well
as county level variables were evaluated. To assess factors asso-
ciated with treatment cost, bivariate and multivariate linear
regression analyses were performed, where log transformed cost
was used as a dependent variable. RESULTS: Resource utiliza-
tion patterns and treatment costs of patients with type-2 diabetes
differ among the race and ethnic groups studied. In the ﬁrst year
of diabetes management, total treatment costs for Hispanics
($7189) and ($6715) were substantially lower than for white
patients ($8549). Although the difference in health care costs
between Caucasians and African-Americans was mostly
accounted for by demographic, clinical, and county level vari-
ability, the cost difference between Hispanics and Caucasians still
persisted with regard to these factors. CONCLUSIONS: The
immediate cost to care for patients with type-2 diabetes is 
substantial in this Medicaid population, regardless of race or 
ethnicity. Moreover, the differences in costs between the groups
are substantial, suggesting that race- or ethnicity-related factors
associated with persistence need to be addressed in optimizing
early therapy.
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OBJECTIVES: Painful neuropathy is a common complication of
diabetic patients. The purpose of this study is to compare the
cost-effectiveness of duloxetine to routine treatment in the 
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management of pain associated with diabetic neuropathy from
a societal perspective. METHODS: The study sample includes
patients enrolled in the 52-week, randomized, multi-center,
open-label extended phase of a duloxetine versus routine treat-
ment trial in the management of pain associated with diabetic
neuropathy. The ﬁrst patient was enrolled in the study on June
14, 2001 and the last patient completed the extended phase study
on April 28, 2003. A sub-population of 233 U.S. patients with
diabetic neuropathic pain was randomized to either duloxetine
60mg BID or routine pain treatment. The primary efﬁcacy
measure was the Medical Outcomes Study Short Form 36 (SF-
36) bodily pain domain (BP). Total costs (direct medical and indi-
rect productivity loss cost), adjusted to 2002 dollars using
Consumer Price Index, were analyzed from a societal perspec-
tive. Bootstrap method was applied to calculate statistical infer-
ence of incremental cost-effectiveness ratio (ICER). RESULTS:
Duloxetine treatment was associated with a signiﬁcant improve-
ment in SF-36 BP score compared with routine treatment (p-
value = 0.05). From societal perspective, duloxetine is both a
more cost-effective (ICER = -$429/1BP, p = 0.04) and dominant
(p = 0.06) therapy compared to routine treatment in the man-
agement of pain associated with diabetic neuropathy. CON-
CLUSIONS: This study shows that duloxetine is more
cost-effective and dominant treatment for painful diabetic neu-
ropathy compared to routine care.
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OBJECTIVE: The microvascular and macrovascular complica-
tions of diabetes are generally associated with poorer health
related quality of life, but few studies have assessed utility values
associated with speciﬁc individual or multiple complications.
This study estimated utilities for the most common complica-
tions, to establish whether patients have a poorer quality of life
than those without complications. METHODS: EQ-5D index
data were generated through cross-sectional postal surveys of
patients on two regional registers in the UK, stratiﬁed according
to the 17 most prevalent individual or multiple complications
(including “none”). Amputation and blindness did not appear in
this list. Subgroup analysis was undertaken on patients without
chronic co-morbidities. RESULTS: Response rates were 62% in
Brighton (n = 589) and 65% in Salford (n = 491). Nine of the
most prevalent complication groups in Brighton and seven in
Salford represented multiple complications. In Brighton, the
lowest mean score was for patients with previous ischaemic heart
disease plus peripheral vascular disease or claudication. Symp-
tomatic neuropathy appeared in ﬁve out of the eight complica-
tion groups, which had signiﬁcantly lower mean scores (p < 0.05)
than the group without complications. Normalising for co-
morbidities did not fundamentally change the ﬁndings, although
mean scores were generally higher in the subgroups without co-
morbidities. Stroke appeared in two, and angina in three, of 
the seven complication groups, which had signiﬁcantly, lower
mean scores (p < 0.05) than the group without complications.
CONCLUSIONS: Patients with the most common diabetic 
complications have a poorer quality of life than those without
complications. Understanding the interaction of different com-
plications on patients’ quality of life will be increasingly impor-
tant as new strategies are explored to reduce the risk of such
complications.
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OBJECTIVES: The objective of this study was to improve the
design of diabetes risk-reduction interventions by quantifying
high-risk patients’ value of diabetes risks relative to the discom-
fort, inconvenience, and costs of diet, exercise, and weight-
loss features of hypothetical diabetes-prevention programs.
METHODS: A web-based, stated-choice survey instrument pre-
sented respondents with a sequence of choices among pairs of
diabetes prevention program features and a “Neither” alterna-
tive. The instrument was pretested with a convenience sample of
16 subjects. The survey was administered to 400 subjects iden-
tiﬁed as high risk (obese, over age 45, 25% minorities) and to
200 subjects identiﬁed as lower risk (not obese, over age 45, 25%
minorities). Each subject evaluated 9 choice tasks describing pro-
grams with varying levels of 7 features: diet, exercise, counsel-
ing, medication, weight loss, cost, and risk reduction. RESULTS:
Discrete-choice patterns reveal the implicit relative importance
of program features. More than half of the subjects evaluated
diet, exercise, or counseling as more important than cost, med-
ication, and weight-loss goal. However, cost proved to be impor-
tant in actual stated choices among programs for over 85% of
subjects. Over half of the subjects indicated they were willing to
incur signiﬁcant discomfort to reduce risks if the baseline dia-
betes risks were greater than 30%, which they are for high-risk
individuals. Obese subjects were more likely to prefer interven-
tions that included medication. CONCLUSIONS: There are sig-
niﬁcant cost-reduction beneﬁts in avoiding the cost of glucose
control and subsequent serious complications of diabetes
patients. However, patient’s adherence to a risk-reduction inter-
vention depends on patients’ perceived value of risk reduction
relative to the of risk-reducing behavior. Patients are more likely
to be adherent to risk-reduction programs with features that
include effective diet and counseling features. Discrepancies
between observed behavior and stated preferences for risk 
reduction may indicated poor perceptions of baseline risks and
risk-reduction beneﬁts.
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OBJECTIVE: Psychological general well-being is an important
aspect of the quality of life of individuals with type-2 diabetes.
The objective of this study was to determine the value of assess-
ing psychological general well-being in diabetes drug therapy
evaluations. METHODS: We administered the Psychological
General Well-Being Schedule (PGWB) to 111 patients with type
2 diabetes (mean age = 55.8 years, 62% male, baseline A1c mean
= 8.2%) participating in a Phase II randomized placebo-
controlled trial of oral anti-diabetes treatment. The PGWB 
consists of 22 items divided into 6 subscales—anxiety, depressed
